NYSE$CVS

CVS Health Corp · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

CVS Health reported Q4 2024 revenue of $97.71 billion, up 4.2% YoY, but experienced a decline in operating income and net income due to pressures in the Health Care Benefits segment. GAAP EPS fell to $1.30 from $1.58, and Adjusted EPS dropped to $1.19 from $2.12.

Headline financials

Total Revenue

$97.7B

Previous: $93.8B+4.2%
EPS (adj)

$1.19

Previous: $2.12-43.9%
Total Medical Membership

27.1M

No prior period
Medical Benefit Ratio

94.8%

No prior period
Pharmacy Claims Processed

499.4M

No prior period
Prescriptions Filled

445.9M

No prior period
Days Claims Payable

44

No prior period
Capital Expenditures

-$768M

Previous: -$911M+15.7%
Net Income

$1.64B

Previous: $2.05B-19.7%
Operating Income

$2.37B

Previous: $3.37B-29.8%
Gross Profit

$12.9B

Previous: $13.9B-7.0%

Revenue & EPS history

CVS Health · Revenue · Quarterly

$97.7B

Q4 2024+4.2%vs Q4 2023
Beat estimate in 12 of 15 quarters(80%)
ActualEstimate

Revenue by segment

CVS Health · $102B total across 3 segments · Q3 2023

  • Health Services
    $46.9B+8.5%
  • Pharmacy & Consumer Wellness
    $28.9B+8.1%
  • Health Care Benefits
    $26.3B+16.8%

Forward guidance

CVS Health provided a 2025 Adjusted EPS guidance range of $5.75 to $6.00, with GAAP EPS expected between $4.58 and $4.83. Cash flow from operations is projected to be approximately $6.5 billion.

Tailwinds

  • Continued revenue growth across key segments, particularly in Pharmacy & Consumer Wellness.
  • Expected improvements in Medicare Advantage star ratings in future years.
  • Focus on cost optimization and operational efficiency improvements.
  • Growth in specialty pharmacy and increased utilization in health services.
  • Expanding digital and in-home health care offerings.

Headwinds

  • Ongoing pressures in the Health Care Benefits segment due to higher utilization rates.
  • Impact of lower Medicare Advantage star ratings affecting reimbursement rates.
  • Declining operating income despite revenue growth.
  • Increased competition in pharmacy and health services markets.
  • Potential macroeconomic headwinds affecting consumer spending.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+0.1%

Avg return

Earnings day

+1.4%

Avg return

5 days after

+1.3%

Avg return

30 days after

56%

41 / 73 earnings

Positive

+14.9%

Q4 2024

Best reaction

-18.5%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026-0.2%+14.3%+19.1%
Q4 2025-0.1%+3.6%+0.4%
Q3 2025-1.9%-4.6%-2.2%
Q2 2025-0.3%+1.8%+17.4%
Q1 2025+4.1%-0.7%-4.0%
Q4 2024+14.9%+19.7%+19.4%
Q3 2024+3.1%+0.8%-0.1%
Q2 2024-0.8%-4.3%-1.0%
Q1 2024-18.5%-17.3%-12.0%
Q4 2023+1.8%+4.8%+1.8%
Q3 2023+0.9%+3.0%-0.8%
Q2 2023+0.5%-0.1%-11.2%
Q1 2023-5.5%-4.2%-3.8%
Q4 2022+4.8%+4.5%-10.3%
Q3 2022+3.4%+6.9%+8.4%
Q2 2022+6.8%+7.0%+4.3%
Q1 2022+1.8%+3.0%-1.1%
Q4 2021-5.0%-7.1%-6.6%
Q3 2021+3.7%+2.9%-0.3%
Q2 2021-4.7%-2.8%+4.1%
Q1 2021+6.9%+9.6%+12.1%
Q4 2020-2.0%-5.1%+0.4%
Q3 2020+10.0%+13.2%+21.3%
Q2 2020-1.3%+1.1%-7.3%
Q1 2020+0.4%+4.3%+11.7%
Q4 2019-2.5%-3.4%-19.2%
Q3 2019+6.6%+6.6%+11.9%
Q2 2019+9.2%+8.6%+15.0%
Q1 2019+4.3%+4.1%-3.7%
Q4 2018-10.8%-12.4%-19.8%
Q3 2018+6.9%+8.3%+3.9%
Q2 2018+4.8%+6.2%+18.1%
Q1 2018-8.4%-9.2%-5.8%
Q4 2017-6.7%-5.7%-6.8%
Q3 2017-0.4%+2.5%+3.1%
Q2 2017+0.4%+0.4%+1.6%
Q1 2017-2.8%-1.1%-4.5%
Q4 2016+1.9%+2.1%+4.4%
Q3 2016-8.2%-10.0%-6.3%
Q2 2016+4.2%+4.2%-0.1%
Q1 2016+2.4%
Q4 2015+3.9%
Q3 2015-3.3%
Q2 2015-1.4%
Q1 2015+0.9%
Q4 2014+3.0%
Q3 2014+1.6%
Q2 2014-0.4%
Q1 2014+2.6%
Q4 2013+2.4%
Q3 2013+3.0%
Q2 2013-4.1%
Q1 2013+1.3%
Q4 2012-1.0%
Q3 2012+0.1%
Q2 2012+1.5%
Q1 2012+2.9%
Q4 2011-1.2%
Q3 2011+6.3%
Q2 2011-5.7%
Q1 2011+3.9%
Q4 2010-0.2%
Q4 2007-0.2%
Q3 2010+3.2%
Q2 2010-2.7%
Q1 2009-2.8%
Q1 2010-2.2%
Q4 2009+1.2%
Q3 2008-17.6%
Q3 2009-17.6%
Q4 2008+1.1%
Q2 2008+1.1%
Q2 2009+1.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro